Northern Trust’s Capricor Therapeutics CAPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12.7M | Buy |
417,543
+66,902
| +19% | +$1.78M | ﹤0.01% | 1945 |
|
|
2025
Q4 | $10.1M | Sell |
350,641
-1,880
| -0.5% | -$24.6K | ﹤0.01% | 2080 |
|
|
2025
Q3 | $2.54M | Sell |
352,521
-18,153
| -5% | -$134K | ﹤0.01% | 2899 |
|
|
2025
Q2 | $3.68M | Sell |
370,674
-9,099
| -2% | -$96.1K | ﹤0.01% | 2643 |
|
|
2025
Q1 | $3.6M | Sell |
379,773
-4,384
| -1% | -$60.9K | ﹤0.01% | 2599 |
|
|
2024
Q4 | $5.3M | Buy |
384,157
+116,086
| +43% | +$2.03M | ﹤0.01% | 2474 |
|
|
2024
Q3 | $4.08M | Buy |
268,071
+138,458
| +107% | +$685K | ﹤0.01% | 2596 |
|
|
2024
Q2 | $618K | Buy |
129,613
+9,299
| +8% | +$51.9K | ﹤0.01% | 3426 |
|
|
2024
Q1 | $817K | Sell |
120,314
-6,915
| -5% | -$33.4K | ﹤0.01% | 3401 |
|
|
2023
Q4 | $622K | Buy |
127,229
+22,269
| +21% | +$72.5K | ﹤0.01% | 3467 |
|
|
2023
Q3 | $359K | Sell |
104,960
-547
| -0.5% | -$3.07K | ﹤0.01% | 3609 |
|
|
2023
Q2 | $504K | Sell |
105,507
-467
| -0.4% | -$2.05K | ﹤0.01% | 3543 |
|
|
2023
Q1 | $447K | Buy |
105,974
+1,165
| +1% | +$5.02K | ﹤0.01% | 3518 |
|
|
2022
Q4 | $405K | Sell |
104,809
-496
| -0.5% | -$2.37K | ﹤0.01% | 3571 |
|
|
2022
Q3 | $631K | Buy |
105,305
+3,905
| +4% | +$20K | ﹤0.01% | 3437 |
|
|
2022
Q2 | $354K | Sell |
101,400
-1,021
| -1% | -$3.62K | ﹤0.01% | 3659 |
|
|
2022
Q1 | $351K | Sell |
102,421
-1,502
| -1% | -$5.92K | ﹤0.01% | 3878 |
|
|
2021
Q4 | $304K | Sell |
103,923
-749
| -0.7% | -$2.62K | ﹤0.01% | 4010 |
|
|
2021
Q3 | $421K | Buy |
104,672
+421
| +0.4% | +$1.92K | ﹤0.01% | 3827 |
|
|
2021
Q2 | $535K | Buy |
104,251
+7,310
| +8% | +$31K | ﹤0.01% | 3683 |
|
|
2021
Q1 | $453K | Sell |
96,941
-39,873
| -29% | -$230K | ﹤0.01% | 3844 |
|
|
2020
Q4 | $469K | Sell |
136,814
-14,551
| -10% | -$63.1K | ﹤0.01% | 3742 |
|
|
2020
Q3 | $795K | Buy |
151,365
+2,894
| +2% | +$16.9K | ﹤0.01% | 3486 |
|
|
2020
Q2 | $683K | Buy |
+148,471
| New | +$647K | ﹤0.01% | 3471 |
|
|
2019
Q2 | – | Sell |
-4,592
| Closed | -$21K | – | 4274 |
|
|
2019
Q1 | $21K | Sell |
4,592
-30
| -0.6% | -$154 | ﹤0.01% | 4126 |
|
|
2018
Q4 | $19K | Buy |
4,622
+30
| +0.7% | +$238 | ﹤0.01% | 4157 |
|
|
2018
Q3 | $48K | Hold |
4,592
| – | – | ﹤0.01% | 4140 |
|
|
2018
Q2 | $62K | Buy |
4,592
+726
| +19% | +$9.88K | ﹤0.01% | 4090 |
|
|
2018
Q1 | $53K | Hold |
3,866
| – | – | ﹤0.01% | 4074 |
|
|
2017
Q4 | $61K | Buy |
3,866
+2,157
| +126% | +$46.7K | ﹤0.01% | 4044 |
|
|
2017
Q3 | $52K | Hold |
1,709
| – | – | ﹤0.01% | 4054 |
|
|
2017
Q2 | $14K | Hold |
1,709
| – | – | ﹤0.01% | 4204 |
|
|
2017
Q1 | $58K | Buy |
+1,709
| New | +$47.4K | ﹤0.01% | 4040 |
|
Other funds holding CAPR
SCM
TCM
VCM
RCM
JHC
Northern Trust's CAPR Position: Q1 2026 in Review
Northern Trust increased its Capricor Therapeutics (CAPR) stake by 19% in Q1 2026, buying an estimated $1.78M and bringing the position to 417,543 shares worth $12.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1945.
Northern Trust first reported a position in CAPR in Q1 2017 and has held it in 33 quarters since. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.
- Northern Trust held 417,543 shares of Capricor Therapeutics worth $12.7M as of Q1 2026.
- Northern Trust bought 66,902 Capricor Therapeutics shares in Q1 2026, an estimated $1.78M.
- Capricor Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #1945 holding.
- Northern Trust first reported a position in Capricor Therapeutics in Q1 2017 and has held it in 33 quarters since.
- 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.